Jarrad King

2 papers in the library · publishing 2024-2026

Papers

QUALITY OF LIFE AND PRODUCTIVITY AMONG ESKETAMINE RESPONDERS IN A REAL-WORLD STUDY IN AUSTRALIA AND NEW ZEALAND

Journal of Psychiatric Research July 1, 2026 Malcolm Hopwood, David Codyre, David Barton et al.

In a post-hoc subgroup analysis of an Early Access Program in Australia and New Zealand, 28 of 84 participants (33.3%) with treatment-resistant depression who received esketamine nasal spray plus a newly-initiated oral antidepressant over 16 weeks were classified as responders (≥50% decrease in HAMD-17 score). Responders showed mean improvements in depression severity (71.2%), quality of life (29.5% on AQoL-8D), and work productivity (≥11.9% on WPAI:SHP), with the largest gains in mental health (32.9%) and overall work productivity loss (35.9%). Results should be interpreted cautiously due to the post-hoc design, short follow-up, small sample, and missing data.

DOI: 10.1016/j.jpsychires.2026.07.011 Depression economics Mental health Productivity Rating scale +8

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.

The British journal of psychiatry : the journal of mental science November 1, 2024 Gero Joks, Steve Su, Jarrad King

A commentary on the KADS study raises concerns about the interpretation of its findings on repeated subcutaneous ketamine injections for treatment-resistant depression. The authors of the commentary aim to clarify points to ensure accurate and balanced information is presented to healthcare professionals, questioning the researchers' discussion of efficacy and safety results from the 4-week randomized double-blind active-controlled trial.

DOI: 10.1192/bjp.2024.79 Full text Major depressive disorder Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression